Effects of Nilvadipine on cytokine-levels and soluble factors in collagen disease complicated with essential hypertension

Clinical and Experimental Hypertension

Volumn 21, Issue 7, 1999, Pages 1177-1188

  Kagawa, H ^a   Nomura, S ^a   Ozaki, Y ^a   Nagahama, M ^a   Fukuhara, S ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Collagen disease; Hypertension; Nilvadipine; SIL 2R; TNF

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYTOKINE; HLA DR ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NILVADIPINE; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HELPER CELL; HUMAN; IMMUNOMODULATION; MALE; POLYMYOSITIS; RHEUMATOID ARTHRITIS; SUPPRESSOR CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION;

EID: 0032825523     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969909052196     Document Type: Article

References (35)

1. Stratta P, Canavese C, Valmaggia P, Rotunno M, Levi E, Bulla A, Vercellone A. Coagulation and fibrinolysis study in systemic lupus erythematosus. Haematological, urinary and tissue parameters. Thromb Haemost 1981; 46: 575-580.
2. Angles-Cano E, Sultan Y, Cluvel J-P. Predisposing factors to thrombosis in systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
3. Rick ME, Hoyer LW. Haemastatic disorders in systemic lupus erythematosus. Clin Rheum Dis 1982; 1: 583-596.
4. Kagawa H, Okubo S, Yasunaga K. Plasma coagulation and fibrinolysis parameters in patients with collagen diseases, and analysis of the multimeric structure of von Willebrand factor (vWF). Int J Hematol 1991; 54: 429-439.
5. Kagawa H, Okubo S, Iwata K, Nomura S, Yasunaga K. Addition of serum from patients with collagen diseases increases to cultured human endothelial cells production and release of von Willebrand factor. Am J Hematol 1993; 42: 309-315.
6. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10; Interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385.
7. Ross R. The pathogenesis of atherosclerosis. Nature 1993; 37: 801-809.
8. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496
9. Libby P, Stephen J, Warner C. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988; 81: 487-498.
10. Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 1992; 116: 1292-1300.
11. Hansson GK, Holm J, Jonnson L. Detection of activated T-lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169-175.
12. Takano S, Kimura A. Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-2029.
13. Tsuchiya N, Shiota M, Yamaguchi A, Ito K. Elevated serum level of soluble HLA class I antigen in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 792-796.
14. Wolf RE, Brolsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988; 31: 729-735.
15. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172-3177.
16. Furuta T, Shibata S, Kodama I, Yamada Y. Cardiovascular effects of FR-34235, a new dihydropyridine slow channel blocker, in isolated rabbit myocardinum and aorta. J Cardiovasc Pharmacol 1983; 5: 836-841.
17. Ohtsuka M, Ono T, Hiroi K, Esumi H, Kikuchi H, Kumada S. Comparison of the cardiovascular effect of FR-34235, a new dihydropyridine, with other calcium antagonists. J Cardiovasc Pharmacol 1983; 5: 1074-1082.
18. Bkaily G, Molyvdass P-A, Ousterhout J, Sperelakiss N. New dihydropyridine drug, nilvadipine, blocks the calcium slow action potential in rat-cultured aortic smooth muscle cells. Eur J Pharmacol 1986; 124: 59-65.
19. Nomoto A, Hirosumi J, Sekiguchi C, Mutoh S, Yamaguchi I, Aoki H. Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery. Atherosclerosis 1987; 64: 255-261.
20. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981; 68: 1366-1369.
21. Ginsburg R, Davis K, Bristow MR, McKennett K, Kodsi SR, Billingham ME, Schroeder J. Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits. Lab Invest 1983;49:154-158.
22. Willis AL, Nagel B, Churchill V, Whyte MA, Smith DL, Mahmud I, Puppione DL. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis 1985;5:250-255.
23. Hirosumi J, Nomoto A, Ohkubo Y, Sekiguchi C, Mutoh S, Yamaguchi I, Aoki H. Inflammatry responses in cuff-induced atherosclerosis in rabbits. Atherosclerosis 1987;64:243-254.
24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
25. Moyer CF, Sajuthi D, Tulli H, Williams JK. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol 1991;138:951-960.
26. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990;65:297-302.
27. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-175.
28. Kawano Y, Takaue Y, Saito S, Sato J, Shimizu T, Suzue T, Hirao A, Okamoto Y, Abe T, Watanabe T. Granulocyte colony stimulating factor (CSF), macrophage-CSF, Granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts. Blood 1993;81:856-860
29. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
30. Roth M, Keul R, Emmons LR, Horl WH, Block LH. Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci USA 1992;89:4071-4075
31. Oda H, Yorioka N, Ito T, Yamashita K, Kushihata S, Yamakido M. Nicardipine hydrochlorides suppresses DNA synthesis in human mesangial cells stimulated with recombinant human (rh) platelet-derived growth factor AA, rh interleukin-1 α, or rh tumor necrosis factor-α. Nephron 1996;73:16-22
32. Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R. Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 1997;15:135-141
33. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of mouse helper T cells. I. definition of according to profiles of lymphokine activities and secrete proteins. J Immunol 1986;136:2348-2357.
34. van der Poll T, Buller H, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-1623.
35. Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994;84:2061-2067.